The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC).
 
Mei Wei
Consulting or Advisory Role - Arvinas; AstraZeneca; bioTheranostics; Gilead Sciences; Merck; Novartis; Relay Therapeutics
Patents, Royalties, Other Intellectual Property - From Ambry Genetics for a software (I)
 
Anthony Elias
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Alexion Pharmaceuticals; Align Oncology; Allergan; Amgen; Bristol-Myers Squibb; Cigna; Exact Sciences; Gilead Sciences; Illumina; Lilly; Merck; Pfizer
Consulting or Advisory Role - Arvinas; Caris Life Sciences; Ellipses Pharma
Research Funding - ImmuneOnco Biopharmaceuticals (Inst); Scorpion Therapeutics (Inst)
 
Karthik Giridhar
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo (Inst); Exact Sciences (Inst); Gilead Sciences (Inst); Lilly (Inst); MJH Live Events (Inst); MJH Live Events (Inst); NeoGenomics Laboratories (Inst); Puma Biotechnology (Inst); Tersera (Inst)
Research Funding - Guardant Health (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - GRAIL; QuantumLeap Health
 
Matthew Goetz
Consulting or Advisory Role - ARC Therapeutics (Inst); ARC Therapeutics (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Atossa Therapeutics (Inst); BeiGene (Inst); bioTheranostics (Inst); BioTheryX; Biovica (Inst); Blueprint Medicines (Inst); Context Therapeutics (Inst); Eagle Pharmaceuticals (Inst); eChinaHealth (Inst); EcoR1 Capital (Inst); Engage Health Media (Inst); Genentech (Inst); Genomic Health (Inst); Genzyme (Inst); Genzyme (Inst); Incyclix Bio (Inst); Intellisphere (Inst); Laekna Therapeutics; Lilly (Inst); Loxo (Inst); Novartis (Inst); Puma Biotechnology (Inst); Rna Diagnostics (Inst); Seagen (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Sermonix Pharmaceuticals (Inst); Tersera
Research Funding - AstraZeneca (Inst); Atossa Genetics (Inst); BioTheryX (Inst); Lilly (Inst); Loxo (Inst); Pfizer (Inst); Sermonix Pharmaceuticals (Inst); SimBioSys (Inst)
Travel, Accommodations, Expenses - Lilly (Inst)
(OPTIONAL) Uncompensated Relationships - Symbios
 
Rita Mukhtar
Research Funding - GE Healthcare
Patents, Royalties, Other Intellectual Property - Patent on the use of fibrin and silver microparticles to promote wound healing. (I)
 
Christos Vaklavas
Employment - Flatiron Health (I)
Honoraria - AstraZeneca; Cardinal Health; Cardinal Health; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Guidepoint Global; Novartis; Pfizer; Pfizer; Seagen
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Daiichi Sankyo; Genentech; Gilead Sciences
Research Funding - AstraZeneca (Inst); AstraZeneca/Daiichi Sankyo (Inst); Daiichi Sankyo/UCB Japan (Inst); Genentech (Inst); H3 Biomedicine (Inst); Incyte (Inst); Innocrin Pharma (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); TRACON Pharma (Inst); Zymeworks (Inst)
Other Relationship - Daiichi Sankyo; Puma Biotechnology; Takeda
(OPTIONAL) Uncompensated Relationships - Genentech
 
Laura van t Veer
Employment - Agendia
Stock and Other Ownership Interests - Agendia; Exai Bio
 
Silver Alkhafaji
No Relationships to Disclose
 
Gillian Hirst
No Relationships to Disclose
 
Hope Rugo
Honoraria - Chugai Pharma; Mylan/Viatris
Consulting or Advisory Role - Bristol Meyer; Napo Pharmaceuticals; Sanofi
Research Funding - Ambryx (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Hoffmann-La Roche AG/Genentech, Inc (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Stemline Therapeutics (Inst)
 
Nan Chen
Employment - GlaxoSmithKline (I)
Consulting or Advisory Role - AstraZeneca; GE Healthcare; Gilead Sciences; Guardant Health; Seagen; Stemline Therapeutics
 
W. Fraser Symmans
Stock and Other Ownership Interests - Delphi Diagnostics; Eiger BioPharmaceuticals; ISIS Pharmaceuticals
Consulting or Advisory Role - AstraZeneca; SAGA Diagnostics
Patents, Royalties, Other Intellectual Property - Intellectual property; Intellectual Property (expired); Intellectual Property (pending)
(OPTIONAL) Uncompensated Relationships - Delphi Diagnostics
 
Alexander Borowsky
Leadership - Histolix
Stock and Other Ownership Interests - Histolix
Consulting or Advisory Role - Tempus
Research Funding - Danaher (Inst)
 
Lamorna Brown Swigart
No Relationships to Disclose
 
Natsuko Onishi
Employment - Artera (I)
Stock and Other Ownership Interests - Artera (I)
 
Douglas Yee
Consulting or Advisory Role - Martell diagnostic
Research Funding - Fusion Pharmaceuticals
 
Nola Hylton
Research Funding - Siemens Healthineers (Inst)
 
Laura Esserman
Consulting or Advisory Role - Blue Cross Blue Shield Association
Research Funding - Moderna Therapeutics (Inst)
Travel, Accommodations, Expenses - Blue Cross Blue Shield Association
(OPTIONAL) Uncompensated Relationships - Quantum Leap Healthcare Collaborative
 
Jo Chien
Consulting or Advisory Role - Genentech/Roche
Research Funding - Amgen (Inst); Merck (Inst); Olema Oncology (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Pending Patent Application for “COMBINATION INCLUDING A CPG-C TYPE OLIGONUCLEOTIDE AND A PD-1 ANTAGONIST FOR TREATING BREAST CANCER”
Travel, Accommodations, Expenses - Genentech/Roche